NCT05070312View on ClinicalTrials.gov

Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

February 7, 2022

Study Completion Date

February 7, 2022

Conditions
Healthy Volunteer
Interventions
BIOLOGICAL

MEDI3506

MEDI3506

DRUG

Placebo

Placebo

Trial Locations (1)

215006

Research Site, Suzhou

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY